ETM
BMY icon

Euclidean Technologies Management’s Bristol-Myers Squibb BMY Stock Holding History

Euclidean Technologies Management’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$204K Hold
2,945
– – 0.19% 69
2022
Q4 		$212K Hold
2,945
– – 0.2% 61
2022
Q3 		$209K Hold
2,945
– – 0.23% 57
2022
Q2 		$227K Hold
2,945
– – 0.23% 60
2022
Q1 		$215K Buy
+2,945
New +$198K 0.2% 72

Other funds holding BMY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Euclidean Technologies Management's BMY Position: Q1 2023 in Review

Euclidean Technologies Management held its Bristol-Myers Squibb (BMY) position steady in Q1 2023 at 2,945 shares worth $204K. The position accounts for 0.19% of the portfolio, ranked #69.

Euclidean Technologies Management first reported a position in BMY in Q1 2022 and has held it in 5 quarters since. The position peaked at $227K in Q2 2022. 2,540 funds tracked by Wall St. Rank hold BMY as of Q1 2023.

  • Euclidean Technologies Management held 2,945 shares of Bristol-Myers Squibb worth $204K as of Q1 2023.
  • Euclidean Technologies Management left its Bristol-Myers Squibb share count unchanged in Q1 2023.
  • Bristol-Myers Squibb made up 0.19% of Euclidean Technologies Management's portfolio in Q1 2023, its #69 holding.
  • Euclidean Technologies Management first reported a position in Bristol-Myers Squibb in Q1 2022 and has held it in 5 quarters since.
  • Euclidean Technologies Management's Bristol-Myers Squibb position peaked at $227K in Q2 2022.
  • 2,540 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2023.

Based on Euclidean Technologies Management's 13F filing for Q1 2023, filed 26 Apr 2023.